Maxpro Ventures
VC Fund
Taipei, Taiwan
Maxpro Ventures is an investment firm focused on breakthrough biomedical technology companies. We identify and invest in such excellent companies worldwide with our private equity and venture capital expertise.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Maxpro Ventures invests in
Stages Maxpro Ventures invests in
Countries Maxpro Ventures invests in
Round sizes
Round size
- Series A
- $10M–$24M
Investment Focus
Industry
- Biotechnology 9 (69%)
- Medical 4 (31%)
- Health Care 3 (23%)
- Therapeutics 3 (23%)
- Pharmaceutical 2 (15%)
Stage
- Venture - Series Unknown 7 (54%)
- Series A 3 (23%)
- Series B 2 (15%)
- Series E 1 (8%)
Country
- Taiwan 10 (77%)
- United States 2 (15%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development. The company was founded in 2017 and based in Laguna Hills, California. | $153M / Series E / Jun 23, 2025 | ||
| Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders. | Series B / Jun 17, 2025 | ||
| StellarCell.Bio is a regenerative medicine company focused on the research, development, and implementation of cell therapy technologies. | Venture - Series Unknown / Jan 01, 2025 | ||
| Full Chain Materials is a Retail company focused on supplying and sourcing a broad range of chemicals and equipment to customers. | Venture - Series Unknown / Jan 01, 2025 | ||
| Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. | $12.5M / Series A / Jan 31, 2024 | ||
| AnHorn Medicines is a drug discovery company that develops therapeutic medicines for cancer, neurodegeneration, and aging diseases. | $10M / Series A / Apr 25, 2023 | ||
| Immunwork develops innovative drugs that combine targeting and effector functions to enhance efficacy and safety. The company focuses on creating ultralong-acting analogues, such as TE-8214, an octreotide derivative, and TE-8035, a modified human insulin. Immunwork's drug pipeline addresses immune system diseases and leverages a proprietarytechnology platform. The company is involved in clinical trials to validate its therapeutic solutions. | $23.7M / Series A / Mar 08, 2022 | ||
| Cross-border remittance service for migrant workers and expats | Venture - Series Unknown / Sep 01, 2021 | ||
| Acepodia is a novel technology platform to arm immune cells with antibodies to cure cancer. The Next Generation of Immunotherapies.Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targetinga different type of cancer. | $47M / Series B / Mar 16, 2021 | ||
| Protect Animal Health is a biotechnology company focused on the research and development of animal healthcare products. | Venture - Series Unknown / Jan 01, 2021 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Maxpro Ventures invest in?
Maxpro Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 13 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Maxpro Ventures invest in?
Maxpro Ventures typically joins rounds of $10M–$24M at Series A. These are whole funding-round sizes, not Maxpro Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Maxpro Ventures took part in.
When did Maxpro Ventures last invest?
The most recent investment recorded for Maxpro Ventures closed in Jun 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
